Introduction: treatment strategies in advanced breast cancer
============================================================

The treatment landscape for advanced breast cancer has changed radically over the last 30--40 years with the refinement of surgical and radiographic techniques, approval of a range of chemotherapy regimens in the adjuvant and metastatic settings, and improvements in screening procedures. A deeper understanding of the molecular pathways underpinning tumor growth has led to the identification and development of a number of targeted therapies with particularly high activity in breast cancer. As an example, the prognosis of women with human epidermal growth factor receptor 2-positive (HER2+) breast cancer has improved dramatically since the introduction of HER2-targeted therapies \[[@mdx226-B1]\]. Meanwhile, in hormone receptor-positive (HR+) breast cancer, the mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to be effective in combination with exemestane \[[@mdx226-B2]\].

Overall, these innovations have led to the earlier detection of breast cancers and better treatments, resulting in significant improvements in patient survival and quality of life. Finding future treatments for breast cancer will depend on gaining more insights into the pathways driving tumor growth and the mechanisms of acquired and *de novo* resistance. Investigational targeted agents currently in clinical development include the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib (BYL719) and the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (LEE011).

Translating basic research into novel therapies in breast cancer
================================================================

A thorough understanding of disease biology and patient needs lies at the heart of developing novel, effective therapies. Novartis has a long-standing heritage in developing treatment options for patients with breast cancer, targeting a range of oncogenic pathways---including the non-steroidal aromatase inhibitor letrozole and everolimus. Activation of the cyclin D--CDK4/6--inhibitor of CDK4 (INK4)--retinoblastoma (Rb) pathway is common in breast cancer, and the efficacy of combined CDK4/6 inhibition with endocrine therapy has been demonstrated in the first- and second-line treatment of advanced breast cancer \[[@mdx226-B3], [@mdx226-B4]\]. These findings encouraged Novartis to expedite the development of ribociclib (LEE011), an orally bioavailable, selective, ATP-competitive inhibitor of CDK4/6 (Figure [1](#mdx226-F1){ref-type="fig"}) \[[@mdx226-B5]\]. In preclinical studies, ribociclib demonstrated high levels of growth inhibition in HR+ breast cancer cell lines \[[@mdx226-B6]\]. Additionally, in xenograft models of HR+ breast cancer, ribociclib demonstrated synergistic antitumor activity in doublet combinations with endocrine therapies including fulvestrant and letrozole \[[@mdx226-B6]\]. In the first-in-human Phase 1 trial of adult patients with advanced solid tumors or lymphoma, single-agent ribociclib displayed promising signs of clinical activity; of 31 patients, 9 experienced stable disease and 1 patient had a partial response \[[@mdx226-B5]\]. Ribociclib clinical development rapidly progressed from early-phase single-agent and dose-finding doublet combination trials to the recent Phase 3 MONALEESA-2 trial based on Phase 1 preliminary data indicating the absence of a drug--drug interaction between ribociclib and letrozole in the CLEE011X2107 trial \[[@mdx226-B7]\]; frequent Data Monitoring Committee meetings mitigated any potential risk. The efficacy and safety of ribociclib is now being investigated in a number of other Phase 3 trials in different patient populations and therapy combinations (Table [1](#mdx226-T1){ref-type="table"}). In March 2017, ribociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of postmenopausal women with HR+, HER2− advanced or metastatic breast cancer was approved by the US Food and Drug Administration (FDA), based on positive results from the planned interim analysis of MONALEESA-2 (discussed below) \[[@mdx226-B8]\]. In addition, based on preclinical data with ribociclib in combination with endocrine therapies and PI3K inhibitors, a series of ongoing Phase 1 and 2 trials are investigating triplet therapy combinations in HR+ breast cancer \[[@mdx226-B9]\]. Table 1Key trials in the ribociclib (LEE011) development programStudyPhaseCombination partnerPatient populationSetting and prior therapy requirements*N*Estimated completionCLEE011X2101 (NCT01237236)1Single agentPatients with Rb+ advanced solid tumors or lymphomas≥1L: Any number of prior therapies132March 2017CLEE011X2102 (NCT01747876)1Single agentPediatric patients with MRT or NB (other tumors with CDK4/6 pathway abnormalities permitted in the dose escalation portion)≥1L: Any number of prior therapies32May 2017MONALEESA-2 (NCT01958021)3LetrozolePostmenopausal women with HR+/HER2− ABC1L: No prior treatment for ABC668Completed (positive interim analysis Jan 2016)MONALEESA-3 (NCT02422615)3FulvestrantMen and postmenopausal women with HR+/HER2− ABC1L and 2L: No prior therapy or progressed on prior ET725Feb 2020MONALEESA-7 (NCT02278120)3Goserelin+tamoxifen or NSAIPre- or perimenopausal women with HR+/HER2− ABC1L: No prior ET for ABC672Feb 2018EarLEE-1 (NCT03078751)3Tamoxifen or letrozole or anastrozole or exemestaneMen and pre- or postmenopausal women with HR+/HER2− high-risk EBCAdjuvant≈2000July 2023EarLEE-2 (NCT03081234)3Tamoxifen or letrozole or anastrozole or exemestaneMen and pre- or postmenopausal women with HR+/HER2− intermediate-risk EBCAdjuvant≈4000Jan 2025CompLEEment-1 (NCT02941926)3bLetrozole+goserelin[^a^](#tblfn1){ref-type="table-fn"}Men and pre- or postmenopausal women with HR+/HER2− ABC1L and 2L: No prior systemic ET and ≤1 prior line of chemotherapy for ABC≈3000May 2021RIBECCA (NCT03096847)3bLetrozole+goserelin[^a^](#tblfn1){ref-type="table-fn"}Men and pre- or postmenopausal women with HR+/HER2− ABC1L, 2L, 3L, and 4L: ≤1 prior line of chemotherapy and ≤2 prior lines of ET for ABC≈500Sept 2019CLEE011X2106 (NCT01857193)1bExemestane±everolimusPostmenopausal women with HR+/HER2− ABC≥1L: Progressed on prior NSAI therapy≈142Sept 2018CLEE011X2107 (NCT01872260)1bLetrozole±alpelisibPostmenopausal women with HR+/HER2− ABC1L (expansion phase): No prior systemic treatment for ABC≈225May 2019CLEE011X2108 (NCT02088684)1b/2Fulvestrant±alpelisibPostmenopausal women with HR+/HER2− ABC≥1L: Progressed on prior AI therapy≈70Sept 2017TRINITI-1 (NCT02732119)1/2Everolimus+exemestaneMen and postmenopausal women with HR+/HER2− ABC≥1L (Phase 2): Progressed on prior ET and a CDK4/6i≈51May 2018CLEE011A2115C (NCT02333370)1bLetrozole or fulvestrant or tamoxifen+goserelin[^b^](#tblfn2){ref-type="table-fn"}Pre- or postmenopausal Asian women with HR+/HER2− ABC1L: No prior treatment for ABC≈86April 2019[^1][^2][^3]
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Community approach to clinical trials: MONALEESA-2 case study
=============================================================

Novartis' strong collaboration with clinicians at trial sites across the world supports fast, efficient, and appropriate patient recruitment onto clinical trials. This was exemplified by the rapid completion of the MONALEESA-2 trial. In MONALEESA-2, the first patient was randomized in January 2014 with enrollment completed after ∼14 months (March 2015); the planned interim analysis was performed after ∼24 months (January 2016). Positive interim results showed that the trial met its primary endpoint, leading to the recommendation by the Independent Data Monitoring Committee to stop the trial early (May 2016). This was followed by the US FDA granting Breakthrough Therapy designation after around 31 months (August 2016), granting Priority Review three months later (November 2016), followed by approval for first-line ribociclib in combination with aromatase inhibitor therapy 5 months later (March 2017). This represents a rapid development timeline from first patient enrollment to trial read-out, considering the median duration of Phase 3 oncology trials in 2014 was ∼50 months \[[@mdx226-B12]\].

Completion of MONALEESA-2 was supported by several key trial design elements. First, a large study steering committee was consulted on the design and conduct of the study; the globally distributed steering committee aided in the consideration of local regulatory requirements and fostered effective inter-investigator communication, resulting in efficient trial conduct with high regional participation. In total, 668 patients were enrolled at 223 sites, across 29 countries worldwide. Second, recruitment was facilitated by permitting patients who had received ≤14 days of prior letrozole or anastrozole onto the trial, increasing the potential pool of eligible patients. Finally, the interim analysis for MONALEESA-2 was planned after 211 PFS events (70% of the planned 302 events), providing an early but mature look at the trial data. The chosen timing of interim analysis and the pre-specified efficacy criteria were guided by early discussions with health authorities, and supported by previous experience in the BOLERO-2 trial \[[@mdx226-B2]\], enabling a stable and robust assessment of treatment effect prior to final analysis. In MONALEESA-2, a stringent Haybittle--Peto type boundary ensured that early trial declaration of superiority would only occur if the HR was ≤0.56 with *P *\<* *0.0000129 \[[@mdx226-B8]\]. Rigorous statistical testing procedures are also in place for the secondary endpoint of overall survival.

Similar testing strategies are being employed throughout the ribociclib development program; by implementing robust statistical criteria for interim analyses, data can potentially be analyzed early for superior efficacy, allowing expedited regulatory filings and, if approved, for patients to benefit from novel therapies at the earliest possible opportunity.

Ribociclib in other patient populations
=======================================

Novartis is also taking an innovative approach to investigating ribociclib in under-served indications that have not been previously investigated with other CDK4/6 inhibitors. Key trials include the following:

MONALEESA-3 (NCT02422615), which is investigating ribociclib in combination with fulvestrant in men (as well as postmenopausal women) with HR+/HER2− advanced breast cancer in the first- and second-line settings. This trial was designed in part to anticipate the results from the Phase 3 FALCON study investigating fulvestrant vs anastrozole for the first-line treatment of HR+ advanced breast cancer. The first patient was enrolled onto MONALEESA-3 in June 2015, and enrollment was completed in May 2016.

MONALEESA-7 (NCT02278120), which is investigating ribociclib in combination with a non-steroidal aromatase inhibitor or tamoxifen plus goserelin in pre- and perimenopausal women with HR+/HER2− advanced breast cancer, in the first-line setting. The first patient was enrolled in November 2014, and enrollment was completed in August 2016.

TRINITI-1 (NCT02732119), which is investigating ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer who have progressed on a prior endocrine therapy and CDK4/6 inhibitor. Recruitment onto this trial is ongoing.

The ribociclib development program therefore includes a wide range of patients. As well as postmenopausal women, the MONALEESA trials include pre- and perimenopausal patient populations, in the first- and later-line settings (as well as specifically in the post-CDK4/6 inhibitor setting); and are also investigating men with advanced breast cancer, who remain a rare and under-served population.

The Novartis pipeline in breast cancer includes a number of promising compounds currently undergoing Phase 1--3 clinical trials, across the full range of breast cancer subtypes (HR+/HER2−, HER2+, and triple-negative breast cancer). In addition to ribociclib, other key Phase 3 compounds include PI3K/mTOR pathway inhibitors.

Conclusions
===========

The development of ribociclib provides an example of rapid drug development, with successful transition directly from early-phase trials to a large-scale Phase 3 trial. The Phase 3 MONALEESA-2 trial was designed to quickly recruit patients and robustly analyze efficacy and safety as early as possible, leading to the combination of ribociclib and an aromatase inhibitor receiving FDA approval for the treatment of advanced breast cancer after the planned interim analysis, approximately 38 months after the first patient was enrolled. Ongoing clinical trials with ribociclib in a range of indications and treatment settings have the potential to increase treatment options for many more patients with advanced breast cancer and other indications in the future.
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[^1]: In men and premenopausal women only.

[^2]: In premenopausal women only.

[^3]: 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line; ABC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; EBC, early breast cancer; ET, endocrine therapy; HER2−, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; MRT, malignant rhabdoid tumor; NB, neuroblastoma; NSAI, non-steroidal aromatase inhibitor; Rb+, retinoblastoma-positive.
